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Polypill eligibility and equivalent 
intake in a Swiss population‑based 
study
Julien Castioni 1,2, Nazanin Abolhassani 1,2*, Peter Vollenweider 1, Gérard Waeber 1 & 
Pedro Marques‑Vidal 1 
The polypill has been advocated for cardiovascular disease (CVD) management. The fraction of the 
population who could benefit from the polypill in Switzerland is unknown. Assess (1) the prevalence 
of subjects (a) eligible for the polypill and (b) already taking a polypill equivalent; and (2) the 
determinants of polypill intake in the first (2009–2012) and second follow‑ups (2014–2017) of a 
population‑based prospective study conducted in Lausanne, Switzerland. The first and the second 
follow‑ups included 5038 and 4596 participants aged 40–80 years, respectively. Polypill eligibility was 
defined as having a high CVD risk as assessed by an absolute CVD risk ≥ 5% with the SCORE equation 
for Switzerland and/or presenting with CVD. Four polypill equivalents were defined: statin + any 
antihypertensive with (A) or without (B) aspirin; statin + calcium channel blocker (CCB) (C); and 
statin + CCB + angiotensin‑converting enzyme inhibitor (D). The prevalence of polypill eligibility was 
20.6% (95% CI 19.5–21.8) and 27.7% (26.5–29.1) in the first and second follow‑up, respectively. 
However, only around one‑third of the eligible 29.5% (95% CI 26.7–32.3) and 30.4% (27.9–33.0) 
respectively, already took the polypill equivalents. All polypill equivalents were more prevalent among 
men, elderly and in presence of CVD. After multivariable adjustment, in both periods, male gender 
was associated with taking polypill equivalent A (OR: 1.93; 95% CI 1.45–2.55 and OR: 1.67; 95% CI 
1.27–2.19, respectively) and polypill equivalent B (OR: 1.52; 95% CI 1.17–1.96 and OR: 1.41; 95% CI 
1.07–1.85, respectively). Similarly, in both periods, age over 70 years, compared to middle‑age, was 
associated with taking polypill equivalent A (OR: 11.71; CI 6.74–20.33 and OR: 9.56; CI 4.13–22.13, 
respectively) and equivalent B (OR: 13.22; CI 7.27–24.07 and OR: 20.63; CI 6.51–56.36, respectively). 
Former or current smoking was also associated with a higher likelihood of taking polypill equivalent A 
in both periods. A large fraction of the population is eligible for the polypill, but only one‑third of them 
actually benefits from an equivalent, and this proportion did not change over time.
Abbreviations
MI  Myocardial infarction
ACEi  Angiotensin converting enzyme inhibitors
ARB  Angiotensin receptors blockers
CCB  Calcium-channel blockers
BB  Beta-blockers
antiHTA  Antihypertensive
CVD  Cardiovascular disease
FDC  Fixed dose combination
Cardiovascular disease (CVD) is the major cause of death and disability  worldwide1. The reduction of CVD 
burden requires strategies that are applied to the entire or to large segments of the  population2. Despite effec-
tive cardiovascular drugs, adherence is suboptimal in both primary and secondary  prevention3. The “polypill”, 
a fixed dose combination of statin, one or more anti-hypertensive drugs with or without aspirin, could increase 
 adherence4,5 and reduce CVD  burden6,7. Several strategies have been proposed for using the polypill: mass treat-
ment for all elderly  subjects8,9; primary prevention among subjects at high CVD  risk10, and secondary prevention 
among patients with established  CVD11. Which strategy is the best is still under  debate12. Currently, it is estimated 
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that a sizable fraction of the general population is already taking the polypill components as separate drugs. 
Replacing these separate drugs by a fixed dose combination (polypill) could improve adherence to treatment 
and reduce CVD. There are different types of polypill equivalents  available13,14, but the fraction of the popula-
tion who could (1) benefit from the polypill or (2) who is already taking the polypill components (i.e., a polypill 
equivalent) as separate drugs is largely unknown.
This study aimed to assess (1) the prevalence of subjects (a) eligible for the polypill and (b) already taking a 
polypill equivalent; and (2) the determinants of polypill intake in the first (2009–2012) and second follow-up 
(2014–2017) of a prospective population-based study conducted in Lausanne, Switzerland. We also assessed 
which components of the different polypills were already prescribed.
Materials and methods
Study population and design. The Colaus/PsyColaus study (http:// www. colaus- psyco laus. ch) is an ongo-
ing prospective survey investigating the biological and genetic determinants of CV risk factors and CVD in the 
population of Lausanne, Switzerland. Detailed descriptions of the study design have been reported  elsewhere15. 
In summary, a non-stratified random sample of the overall population of Lausanne aged between 35 and 75 years 
was drawn. The following inclusion criteria were applied: (a) written informed consent; (b) willingness to take 
part in the examination and to provide blood samples. Recruitment began in June 2003 and ended in May 2006 
and included 6733 participants. Participation rate was 41%. The evaluation included an interview, a physical 
exam, blood sampling and a set of questionnaires.
The follow-up visit was similar to the baseline evaluation and was performed between April 2009 and Sep-
tember 2012, five and a half years on average after the collection of baseline data, and 5064 subjects participated; 
out of them, 5038 (99.5%) who had CVD risk data were included in this study. Similarly, for the second follow 
up (2014–2017), 4881 subjects participated; out of them 4596 (94.2%) who had CVD risk data were included in 
the study. The data from the first and second follow-ups were used in this study (Supplemental Figure 1, panels 
A and B, respectively).
Data collected. CVD, lifestyle and medication status were assessed by questionnaire. CVD was defined 
as personal history of myocardial infarction (MI), unstable or stable angina, coronary artery bypass grafting, 
stroke, transient ischemic attack or peripheral arterial disease. Whenever possible, CVD reported by participants 
was documented and adjudicated by an independent panel of experts. Smoking status was categorized into 
never, former and current as reported. Medications were assessed by questionnaire and further confirmed by 
interview, where subjects were asked to provide the names of all prescribed and over-the-counter drugs regularly 
taken over the last 6 months. No specific information was collected whether it was the general practitioner or the 
cardiologist who prescribed the medications.
Polypill eligibility was defined as presenting with previous CVD (secondary prevention) or, in the absence of 
CVD, an absolute CVD risk ≥ 5% assessed by the SCORE equation for  Switzerland16 (primary prevention). Four 
commercially available polypill equivalents were defined: equivalent A: aspirin + statin + any antihypertensive; 
equivalent B: no aspirin + statin + any antihypertensive; equivalent C: no aspirin + statin + calcium channel blocker 
(equivalent to Caduet in Switzerland); equivalent D: no aspirin + statin + calcium channel blocker + angiotensin-
converting enzyme inhibitor (equivalent to Triveram in Switzerland). The last two are the only approved polypills 
in Switzerland.
Statistical analysis. Statistical analyses were conducted separately for each survey period (2009–2012 
and 2014–2017). Analyses were performed using STATA software 16.0 (Stata Corp, College Station, TX, USA). 
Descriptive results were expressed as number of participants (percentage) for all categorical variables. Exact 
Poisson confidence intervals for prevalence rates for polypill eligibility and for each polypill equivalent were 
obtained using the ci proportions command of Stata. Bivariate analysis comparing the distribution of the dif-
ferent covariates (i.e. gender, age group…) within each polypill equivalent (use/non-use) was performed using 
chi-square or Fisher’s exact test. Multivariate analysis assessing which covariates were associated with use of 
each polypill equivalent was conducted using logistic regression with the polypill equivalent (use/non-use) as 
dependent variable and gender (man, woman), age group ([40–50], [50–60], [60–70], [70+]), smoking status 
(never, former, current) and history of CVD (yes, no) as independent variables. Results were expressed as odds 
ratio (OR) and 95% confidence interval (CI). A two-sided test p-value below 0.05 was considered statistically 
significant.
Ethical statement. The institutional Ethics Committee of the University of Lausanne, which afterwards 
became the Ethics Commission of Canton Vaud (http:// www. cer- vd. ch) approved the baseline CoLaus study 
(reference 16/03). The approval was renewed for the first (reference 33/09) and the second (reference 26/14) fol-
low-ups. The study was performed in agreement with the Helsinki declaration and its former amendments, and 
in accordance with the applicable Swiss legislation. Written informed consent was obtained from all participants.
Results
Characteristics of the participants. The characteristics of the included and excluded participants are 
summarized in supplemental Table 1. In the first follow-up, of the 5064 participants available, 26 (0.5%) were 
excluded; no differences were found between included and excluded participants. In the second follow-up, of 
the 4881 participants available, 285 (5.8%) were excluded; excluded participants were more frequently in the age 
group [60–70] and less frequently former smokers than included participants.
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Prevalence of polypill eligibility and polypill equivalents. The distribution of eligibility and any 
polypill equivalents intake are summarized in supplemental Table 2. Prevalence of polypill (primary and sec-
ondary) eligibility and of the different polypill equivalents is summarized in Table 1. The prevalence of polypill 
eligibility, based on previous CVD or a CVD SCORE risk ≥ 5%, increased from one-fifth in the first follow-up to 
over one quarter of participants in the second. The majority of eligible subjects were in the primary prevention 
arm. The prevalence of eligible subjects taking polypill components was lower and around one-third of the eligi-
ble subjects in the first and second follow-up. Polypill equivalent A had the highest prevalence in both periods, 
followed by B, C and D.
Determinants of polypill equivalent use. The bivariable and multivariable associations between 
selected sociodemographic and clinical variables and the type of polypill equivalent used are summarized in 
Tables 2 and 3, respectively. Irrespective of the type of polypill equivalent, in both periods, the prevalence was 
higher among men, the elderly and participants with a history of CVD (Table 2). After multivariable adjust-
ment, male gender, increasing age or history of CVD were associated with a higher likelihood of taking polypill 
equivalents A or B in both periods, and former or current smokers with a higher likelihood of taking polypill 
equivalent A in both periods (Table 3).
Distribution of polypill components. The distribution of polypill components is summarized in supple-
mental Table 3. The most prescribed component was antihypertensive drugs, of which the most prescribed were 
angiotensin receptor blockers, followed by beta-blockers. Statins were the most frequent prescribed hypolipidae-
mic drug and aspirin was the most frequently prescribed antiplatelet drug.
Discussion
In this population-based study, over one-fifth and one-fourth of the participants were eligible for a polypill in 
two time points 5 years apart. Nevertheless, only one-third of them actually benefits from an equivalent, and 
this proportion did not change over time. Male gender, increasing age or history of CVD were associated with 
a higher likelihood of taking a polypill equivalent.
Prevalence of polypill eligibility and polypill intake. The eligibility for polypill is a matter of debate, 
especially in primary prevention, and can explain the low prevalence of polypill equivalent in our study in com-
parison to eligible subjects, based on the SCORE equation for Switzerland and previous  CVD16. In comparison, 
the intake of polypill components was also low in a study in the US, which considered age ≥ 55 years and a his-
tory of CVD as polypill eligibility criteria. They showed that 37.3% of US adults ≥ 55 years and 57.0% of those 
with a history of CVD were taking statins and the use of other polypill medications was also  low17. Such results 
can be comparable with ours and the higher intake of polypill can be due to the different eligibility criteria. The 
difference between use of polypill in secondary, compared to the primary prevention, was lower which can be 
due to the broader support for the use of polypill in secondary prevention of  CVD18. Our results imply a gap 
between an individual cardiovascular risk target approach and a population-based global strategy that should 
co-exist to tackle the burden of CVD.
Although polypills have been approved in more than 30 countries and the effectiveness in preventing major 
CV events, increasing medication adherence and lowering number of adverse events has been reported, their 
availability remains  limited13,19. A large availability, with many types and doses combination, is essential for 
polypill in primary high risk and secondary prevention as demonstrated in an Australian study, where, even 
if 62.4% of the patients were still taking the polypill after 18 months, 47.4% of them had additional classes of 
antihypertensive drugs  prescribed5. Even considering only fixed drug combination for antihypertensive therapy, 
Table 1.  Prevalence of polypill eligibility and of the different polypill equivalents, Colaus study, Lausanne, 
Switzerland, 2009–2012 and 2014–2017. Results are expressed as percentage and 95% confidence 
interval. a Aspirin + statin + any antihypertensive. b No aspirin + statin + any antihypertensive. c No 
aspirin + statin + calcium channel blocker (equivalent to Caduet in Switzerland). d No aspirin + statin + calcium 
channel blocker + angiotensin-converting enzyme inhibitor (equivalent to Triveram in Switzerland).
2009–2012 2014–2017
Polypill eligibility
All 20.6 (19.5–21.8) 27.7 (26.5–29.1)
Primary prevention 12.8 (11.9–13.7) 16.5 (15.4–17.6)
Secondary prevention 7.8 (7.1–8.6) 11.3 (10.4–12.2)
Polypill equivalents intake among eligible
Any 29.5 (26.7–32.3) 30.4 (27.9–33.0)
Equivalent  Aa 19.7 (17.4–22.3) 19.0 (16.9–21.2)
Equivalent  Bb 9.7 (8.0–11.7) 11.5 (9.8–13.3)
Equivalent  Cc 6.6 (5.2–8.3) 7.4 (6.0–8.9)
Equivalent  Dd 2.6 (1.7–3.8) 2.0 (1.3–2.9)
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Table 2.  bivariate associations between selected clinical variables and type of polypill equivalent, CoLaus 
study, Lausanne, Switzerland, 2009–2012 and 2014–2017. Results are expressed as number (row percentage). 
Equivalent A: aspirin + statin + any antihypertensive; equivalent B: no aspirin + statin + any antihypertensive; 
equivalent C: no aspirin + statin + calcium channel blocker; equivalent D: no aspirin + statin + calcium channel 
blocker + angiotensin-converting enzyme inhibitor. Between-group comparisons performed using chi-square 
or Fisher’s exact test (§).
2009–2012 2014–2017
A B C D A B C D
Gender
Woman 97 (3.6) 119 (4.4) 46 (1.7) 12 (0.5) 119 (4.7) 128 (5.1) 59 (2.3) 15 (0.6)
Man 182 (7.8) 144 (6.1) 81 (3.5) 28 (1.2) 204 (9.9) 138 (6.7) 84 (4.1) 22 (1.1)
p-value  < 0.001 0.006  < 0.001 0.003  < 0.001 0.021 0.001 0.077
Age group
[40–50] 16 (1.1) 13 (0.9) 9 (0.6) 3 (0.2) 6 (1.1) 3 (0.5) 1 (0.2) 1 (0.2)
[50–60] 44 (2.9) 50 (3.3) 25 (1.6) 8 (0.5) 37 (2.5) 38 (2.6) 11 (0.8) 1 (0.1)
[60–70] 101 (7.5) 118 (8.8) 43 (3.2) 8 (0.6) 83 (6.8) 74 (6.1) 34 (2.8) 10 (0.8)
[70+] 118 (16.0) 82 (11.1) 50 (6.8) 21 (2.9) 197 (14.7) 151 (11.3) 97 (7.2) 25 (1.9)
p-value  < 0.001  < 0.001  < 0.001  < 0.001§  < 0.001  < 0.001  < 0.001  < 0.001§
Smoking status
Never 72 (3.6) 103 (5.1) 40 (2.0) 8 (0.4) 81 (4.6) 107 (6.0) 46 (2.6) 11 (0.6)
Former 155 (8.3) 113 (6.0) 62 (3.3) 23 (1.2) 158 (9.3) 99 (5.9) 57 (3.4) 16 (1.0)
Current 51 (4.7) 47 (4.3) 25 (2.3) 9 (0.8) 61 (7.7) 38 (4.8) 25 (3.1) 5 (0.6)
p-value  < 0.001 0.125 0.026 0.014  < 0.001 0.430 0.386 0.483
History of CVD
No 192 (3.9) 242 (5.0) 97 (2.0) 29 (0.6) 173 (4.1) 217 (5.1) 103 (2.4) 21 (0.5)
Yes 87 (52.7) 21 (12.7) 30 (18.2) 11 (6.7) 150 (43.6) 49 (14.2) 40 (11.6) 16 (4.7)
p-value  < 0.001  < 0.001  < 0.001  < 0.001  < 0.001  < 0.001  < 0.001  < 0.001
Table 3.  Multivariable association between selected clinical variables and type of polypill equivalent, 
CoLaus study, Lausanne, Switzerland, 2009–2012 and 2014–2017. Results are expressed as odds ratio (95% 
confidence interval). Equivalent A: aspirin + statin + any antihypertensive; equivalent B: no aspirin + statin + any 
antihypertensive. Statistical analysis using logistic regression. Significant (p < 0.05) odds ratios are indicated in 
bold.
2009–2012 2014–2017
Polypill equivalent A Polypill equivalent B Polypill equivalent A Polypill equivalent B
Gender
Woman 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
Man 1.93 (1.45–2.55) 1.52 (1.17–1.96) 1.67 (1.27–2.19) 1.41 (1.07–1.85)
Age group
[40–50] 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
[50–60] 2.27 (1.26–4.08) 3.64 (1.97–6.74) 1.91 (0.79–4.62) 4.76 (1.46–15.50)
[60–70] 5.83 (3.37–10.06) 10.48 (5.87–18.72) 4.76 (2.03–11.17) 11.15 (3.49–35.64)
[70+] 11.71 (6.74–20.33) 13.22 (7.27–24.07) 9.56 (4.13–22.13) 20.63 (6.51–65.36)
p-value for trend  < 0.001  < 0.001  < 0.001  < 0.001
Smoking status
Never 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
Former 1.86 (1.35–2.55) 0.99 (0.74–1.31) 1.69 (1.24–2.31) 0.81 (0.60–1.08)
Current 1.60 (1.10–2.39) 0.98 (0.68–1.41) 2.11 (1.43–3.10) 0.89 (0.60–1.31)
p-value for trend 0.023 0.920  < 0.001 0.549
History of CVD
No 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
Yes 14.65 (10.21–21.02) 1.50 (0.92–2.46) 12.34 (9.23–16.50) 1.93 (1.33–2.78)
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availability remains poor. For example, in an American study, the most frequently filled fixed drug combination 
lisinopril/HCTZ was marketed only in 3 doses, although 20 combinations are  possible21. In the Swiss market, 
no polypill with aspirin exists although more than one out of 20 participants could benefit from it, and only two 
equivalents without aspirin exist (C and D). This underlines the potential benefits of a larger availability of a 
polypill in Switzerland to improve adherence in primary or secondary preventive approach.
Determinants of polypill equivalents intake. Male gender, increased age and previous history of CVD 
were associated with higher frequency of the polypill equivalents intake; this observation is consistent with 
gender and age differences in CVD risk  factors16,20. For polypill equivalent A (aspirin + statin + any hypertensive 
drugs), also a positive association with smoking and previous history of CVD was found in both first and second 
follow-ups. For polypill equivalent B (no aspirin + statin + any hypertensive drugs), the association with previous 
history of CVD was only significant in the second follow-up.
Prevalence of polypill components. Antihypertensive drugs are the most frequently prescribed polypill 
component (one quarter of the subjects). This could reflect the high proportion of hypertension in the Swiss 
population, estimated as 36%21, and a high adherence to hypertension target treatment  recommendations22. 
Regarding antihypertensive drug treatment, studies showed polypills containing multiple low doses of BP-lower-
ing drugs produce more effective BP lowering than the use of fewer separate BP-lowering drugs at higher doses, 
without an increase in adverse  effects7,18. In our study, angiotensin receptor blockers were the most used hyper-
tensive drug class. It is quite different from other studies where ACEI inhibitors were the most frequently pre-
scribed class, as shown in an Australian study comparing the adherence of high risk and established CV patients 
to a polypill group (simvastatin, lisinopril and atenolol or HCTZ) vs standard medication  group5. In this study, 
all patients were treated by one of the 38 different blood pressure-lowering medications. ACE inhibitors are the 
most prescribed followed by BB and then ARB. In USA, Wang et al. examined prescriptions fill rates for dys-
lipidemia, diabetes and hypertension treatments using claims data from a large national insurer for > 14 million 
 people23. The most prescribed combination was a statin and hypertensive molecule of which ACEi was the most 
frequent, followed by BB, CCB and ARB. The switch between ACEi and ARB between our study and two others 
could be explained by the higher risk profile of the subjects in the mentioned studies. Also, easy access to and 
marketing of ARB in Switzerland could play a role. Aspirin is much more frequent than other antiplatelet medi-
cations as it is the only one to be indicated in primary prevention. Statins are by far the most prescribed hypolipi-
daemic drug class according to the Swiss atherosclerosis association Swiss recommendations (http:// www. gsla. 
ch). Nevertheless, another study in Switzerland also showed no parallel increase in hypolipidemic drugs along 
with increased dyslipidaemia prevalence and its management remained far from optimal in both primary and 
secondary  prevention24. Also, a study in 78 centers from 16 European countries revealed that large proportions 
of people at high CVD risk have inadequate control of blood pressure, lipids and  diabetes25. Suboptimal man-
agement of coronary patients was reported in a 24 European countries in  201526 and further in 27 European 
countries in  201927. In addition, there are differences in guidelines of the use of statins in primary prevention 
in Europe and other countries that could also contribute to the low use of this drug class in this  indication28,29.
Strengths and limitations. This study evaluates polypill eligibility in a general population sample of more 
than 6000 persons. Contrary to the polypill eligibility, we assessed the real life intake of polypill equivalents, 
defined by the intake of separated components of polypill, and its change in five years.
As limitations, we could cite the selection bias of the general population, described  elsewhere15. In addition, 
as drugs data were self-reported, it might be prone to recall bias and finally underestimation. However, our 
results can provide at least an estimation of the real life polypill intake and of the gap to the theoretic eligibility. 
The results should be interpreted cautiously due to the certain criteria for eligibility that we used in this study 
i.e. having a high CVD risk and/or presenting with CVD, could be different in other countries and even largely 
underestimated if following mass treatment criteria as suggested by Wald and  colleagues9. Using this criterion 
such as age  + 50 years, the theoretic eligibility would be 72% and 88% in the two follow-ups, respectively, and 
the gap with real life even larger as only about one-seventh of them already taking polypill equivalents at both 
periods. In addition, we used SCORE for CVF risk stratification, however, GSLA score may be also used in Swit-
zerland. Furthermore, this was a monocentric study and might not be fully generalizable to other places with 
different health system and availability of polypills. Even, within a country like Switzerland, different prescription 
prevalence across cantons has been  reported30 so generalizability should be considered given such limitations.
Conclusion
In this prospective study in Swiss community-dwelling subjects, over one-fifth and one-fourth were eligible for 
a polypill. Nevertheless, only one-third of them actually benefits from an equivalent, and this proportion did 
not change over time.
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Supplemental table 1: characteristics of included and excluded participants, Colaus study, Lausanne, 
Switzerland, 2009-2012 and 2014-2017. 
 First follow-up (2009-2012) (N=5064) Second follow-up (2014-2017) (N=4881) 
 Included Excluded P-value Included Excluded P-value 
All  5038 (99.5) 26 (0.5)  4596 (94.2) 285 (5.8)  
Gender   0.968   0.462 
Woman 2693 (53.5) 14 (53.8)  2526 (55.0) 163 (57.2)  
Man 2345 (46.5) 12 (46.2)  2070 (45.0) 122 (42.8)  
Age group   0.653   0.002 
[40-50[ 1421 (28.2) 10 (38.5)  561 (12.2) 19 (6.7)  
[50-60[ 1533 (30.4) 7 (26.9)  1474 (32.1) 96 (33.7)  
[60-70[ 1348 (26.8) 5 (19.2)  1222 (26.6) 99 (34.7)  
[70+ 736 (14.6) 4 (15.4)  1339 (29.1) 71 (24.9)  
Smoking status   0.813   0.001 
Never 2025 (40.7) 10 (38.5)  1781 (41.7) 105 (46.9)  
Former 1874 (37.6) 9 (34.6)  1692 (39.6) 62 (27.7)  
Current 1082 (21.7) 7 (26.9)  798 (18.7) 57 (25.4)  
History of CVD   0.422 §   <0.001 § 
No 4873 (96.7) 26 (100.0)  4252 (92.5) 285 (100.0)  
Yes 165 (3.3) 0 (0.0)  344 (7.5) 0 (0.0)  
Results are expressed as number (percentage). Between-group comparisons performed using chi-square 




Supplemental table 2: Prevalence of polypill eligibility and any polypill equivalents intake, Colaus study, 
Lausanne, Switzerland, 2009-2012 and 2014-2017. 
 Eligible, 2009-2012 Eligible, 2014-2017 
Any polypill equivalent intake No Yes No Yes 
No 3120 887 3763 733 




Supplemental table 3: Drugs prescribed, Colaus study, Lausanne, Switzerland, 2009-2012 and 2014-
2017. 
Prescribed Drugs 2009-2012 (N=5038) 2014-2017 (N=4596) 
Antiplatelet drugs   
Any 585 (11.6) 699 (12.8) 
Aspirin 559 (11.1) 655 (14.3) 
Hypolipidaemic drug treatment   
Any 932 (18.5) 936 (20.4) 
Statins 880 (17.5) 876 (19.1) 
Other hypolipidemic drugs 79 (1.6) 91 (2.0) 
Antihypertensive drug treatment   
Any 1352 (26.3) 1525 (33.2) 
Angiotensin receptor blockers 654 (13.0) 765 (16.6) 
ACE inhibitors 358 (7.1) 408 (8.9) 
Beta-blockers 452 (9.0) 525 (11.4) 
Calcium channel blockers 271 (5.4) 328 (7.1) 
Diuretics 405 (8.0) 491 (10.7) 
Hydrochlorothiazide 259 (5.1) 333 (7.3) 
Other antihypertensive drugs § 18 (0.4) 25 (0.5) 
Results are expressed as number of participants (percentage). § peripheral vasodilators or post-synaptic 
stimulators.  
 
